Your search returned 15 results.

Results
	1.	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors: Swain, Sandra M PMID: 24129974 Year: 2013 Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM DOI: http://dx.doi.org/10.1007/s10549-013-2710-z Add to cart (remove)
	2.	Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. MedStar authors: McCarron, Edward C Swain, Sandra M PMID: 28954297 Year: 2018 Citation: Journal of the National Cancer Institute. 110(2), 2018 Feb 01 Institution: MedStar Franklin Square Medical Center Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Bandos H, Brufsky AM, Fehrenbacher L, Ganz PA, Julian TB, Margolese RG, McCarron EC, Melnikow J, Rivera DR, Sturtz K, Swain SM, Wade JL 3rd DOI: https://dx.doi.org/10.1093/jnci/djx162 Add to cart (remove)
	3.	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 25693012 Year: 2015 Citation: New England Journal of Medicine. 372(8):724-34, 2015 Feb 19. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1056/NEJMoa1413513 Add to cart (remove)
	4.	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24869931 Year: 2014 Citation: Oncologist. 19(7):693-701, 2014 Jul. Institution: Washington Cancer Institute Form of publication: Journal Article All authors: Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2014-0033 Add to cart (remove)
	5.	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors: Swain, Sandra M PMID: 23475636 Year: 2013 Citation: Oncologist. 18(3):257-64, 2013. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2012-0448 Add to cart (remove)
	6.	Report from Session III of the Second International Colloquium on Cardio-oncology: Cardio-oncological management of patients. [Review] MedStar authors: Barac, Ana PMID: 31784042 Year: 2019 Citation: Seminars in Oncology. 46(6):408-413, 2019 12. Institution: MedStar Heart & Vascular Institute Medline publication type: Journal Article Review Form of publication: Journal Article All authors: Barac A, Cardinale DM, Khandheria BK, Lenihan D, Minotti G, Torbicki A DOI: https://dx.doi.org/10.1053/j.seminoncol.2019.11.002 Add to cart (remove)
	7.	Avastin withdrawal symptoms. MedStar authors: Lynce, Filipa Swain, Sandra M PMID: 22263961 Citation: Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb. Institution: Washington Cancer Institute Medline publication type: Editorial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Lynce F, Swain SM DOI: http://dx.doi.org/10.1517/14656566.2012.652088 Add to cart (remove)
	8.	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 23868905 Year: 2013 Citation: Annals of Oncology. 24(10):2630-5, 2013 Oct. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM DOI: http://dx.doi.org/10.1093/annonc/mdt274 Add to cart (remove)
	9.	A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. MedStar authors: Trivedi, Neel PMID: 29610115 Year: 2018 Citation: Blood Advances. 2(7):762-768, 2018 Apr 10 Institution: MedStar Washington Hospital Center Department: Hematology and Oncology Medline publication type: Journal Article Form of publication: Journal Article All authors: Cheson BD, Khan N, Ramzi P, Skarbnik A, Trivedi N, Ujjani C, Wang H DOI: https://dx.doi.org/10.1182/bloodadvances.2017015263 Add to cart (remove)
	10.	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors: Swain, Sandra M PMID: 23602601 Year: 2013 Citation: Lancet Oncology. 14(6):461-71, 2013 May. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1016/S1470-2045(13)70130-X Add to cart (remove)
	11.	Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. MedStar authors: Kumar, Anjali S PMID: 26187751 Citation: Lancet Oncology. 16(8):957-66, 2015 Aug. Institution: MedStar Washington Hospital Center Department: Surgery/Colorectal Surgery Medline publication type: Clinical Trial, Phase II Journal Article Multicenter Study Research Support, N.I.H., Extramural Form of publication: Journal Article All authors: Avila K, Cataldo PA, Chow OS, Coutsoftides T, Dietz DW, Fichera A, Garcia-Aguilar J, Herzig DO, Hunt SR, Kumar AS, Marcet JE, Oommen S, Patil S, Polite BN, Smith DD, Stamos MJ, Ternent CA, Timing of Rectal Cancer Response to Chemoradiation Consortium, Varma MG DOI: http://dx.doi.org/10.1016/S1470-2045(15)00004-2 Add to cart (remove)
	12.	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors: Swain, Sandra M PMID: 22276821 Year: 2012 Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26. Institution: Washington Cancer Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Form of publication: Journal Article All authors: Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1056/NEJMoa1111097 Add to cart (remove)
	13.	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors: Swain, Sandra M PMID: 34890214 Year: 2022 Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10. Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP DOI: https://dx.doi.org/10.1200/JCO.21.00896 Add to cart (remove)
	14.	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors: Swain, Sandra M PMID: 24095300 Year: 2013 Citation: Lancet Oncology. 14(12):1183-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N DOI: http://dx.doi.org/10.1016/S1470-2045(13)70411-X Add to cart (remove)
	15.	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. MedStar authors: Rao, Suman PMID: 30620668 Year: 2019 Citation: Journal of Clinical Oncology. 37(7):537-546, 2019 03 01. Institution: Medstar Franklin Square Medical Center Medline publication type: Journal Article Form of publication: Journal Article All authors: Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riccio A, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Vandormael K, Yang J DOI: https://dx.doi.org/10.1200/JCO.18.00149 Add to cart (remove)

Powered by Koha